12:00 AM
 | 
Sep 23, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Prophage vitespen: Updated Phase II data

Updated data from a single-arm, U.S. Phase II trial in 46 patients with newly diagnosed GMB showed that intradermal Prophage G-100 plus standard of care (SOC) radiation and temozolomide led to a median PFS of 17.8 months with a 12-month PFS rate of 63% and a 24-month PFS rate of 20%. Additionally, Prophage G-100 plus SOC led to a...

Read the full 272 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >